TipRanks
Advertisement
Advertisement

MBRX Stock Latest News

Sara Nik Reiterates Buy on Moleculin as MIRACLE Trial De‑Risks AnnAraC; $3 Price Target Maintained
RatingsSara Nik Reiterates Buy on Moleculin as MIRACLE Trial De‑Risks AnnAraC; $3 Price Target Maintained
20h ago
MBRX
Moleculin Completes Enrollment in Pivotal AML Trial
PremiumCompany Announcements
Moleculin Completes Enrollment in Pivotal AML Trial
24h ago
8K
MBRX
Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial
PremiumThe Fly
Moleculin Biotech completes enrollment in Part A of Phase 2/3 R/R MIRACLE trial
1d ago
MBRX
Moleculin Highlights Annamycin Cardiac Safety in New Analysis
PremiumCompany Announcements
Moleculin Highlights Annamycin Cardiac Safety in New Analysis
2d ago
8K
MBRX
Moleculin Biotech announces publication of analysis of Annamycin in Frontiers
PremiumThe Fly
Moleculin Biotech announces publication of analysis of Annamycin in Frontiers
2d ago
MBRX
Moleculin Highlights Immune-Driven Annamycin Pancreatic Cancer Data
PremiumCompany AnnouncementsMoleculin Highlights Immune-Driven Annamycin Pancreatic Cancer Data
5d ago
8K
MBRX
Moleculin Secures Mexican Patent Strengthening Annamycin IP Portfolio
Premium
Company Announcements
Moleculin Secures Mexican Patent Strengthening Annamycin IP Portfolio
7d ago
8K
MBRX
Moleculin Biotech secures Mexican patent protecting Annamycin through 2040
Premium
The Fly
Moleculin Biotech secures Mexican patent protecting Annamycin through 2040
7d ago
MBRX
Moleculin Biotech Faces Nasdaq Delisting Risk After Notice
PremiumCompany Announcements
Moleculin Biotech Faces Nasdaq Delisting Risk After Notice
12d ago
8K
MBRX
Moleculin Showcases New Annamycin Data at September Conferences
PremiumCompany Announcements
Moleculin Showcases New Annamycin Data at September Conferences
16d ago
8K
MBRX
Moleculin Biotech Updates Investors with New Presentation
PremiumCompany Announcements
Moleculin Biotech Updates Investors with New Presentation
30d ago
8K
MBRX
Analyst Maintains Buy on Advancing MIRACLE Phase 3 Trial, Trims Price Target to $3 on Financing Dilution
PremiumRatings
Analyst Maintains Buy on Advancing MIRACLE Phase 3 Trial, Trims Price Target to $3 on Financing Dilution
1M ago
MBRX
Moleculin Biotech price target lowered to $3 from $22 at H.C. Wainwright
PremiumThe FlyMoleculin Biotech price target lowered to $3 from $22 at H.C. Wainwright
1M ago
MBRX
Moleculin Biotech (MBRX) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Moleculin Biotech (MBRX) Q2 Earnings Cheat Sheet
1M ago
MBRX
Moleculin: Buy Rating Maintained as MIRACLE Trial Progress Offsets Dilution; McCarthy Trims Price Target After Equity Financing
Premium
Ratings
Moleculin: Buy Rating Maintained as MIRACLE Trial Progress Offsets Dilution; McCarthy Trims Price Target After Equity Financing
2M ago
MBRX
Moleculin Biotech completes $9.3M equity financing
PremiumCompany Announcements
Moleculin Biotech completes $9.3M equity financing
2M ago
8K
MBRX
Moleculin Biotech updates preliminary blinded results from MIRACLE trial Part A
PremiumThe Fly
Moleculin Biotech updates preliminary blinded results from MIRACLE trial Part A
2M ago
MBRX
Moleculin Biotech Highlights Promising MIRACLE Trial Remission Data
PremiumCompany Announcements
Moleculin Biotech Highlights Promising MIRACLE Trial Remission Data
2M ago
8K
MBRX
Moleculin Biotech files to sell 4.57M shares of common stock, warrants
PremiumThe Fly
Moleculin Biotech files to sell 4.57M shares of common stock, warrants
2M ago
MBRX
Moleculin Biotech announces unblinded efficacy results from MIRACLE trial Part A
PremiumThe FlyMoleculin Biotech announces unblinded efficacy results from MIRACLE trial Part A
3M ago
MBRX
Moleculin Biotech Updates Investors With New Presentation
Premium
Company Announcements
Moleculin Biotech Updates Investors With New Presentation
3M ago
8K
MBRX
Moleculin Biotech Reports Promising Annamycin AML Trial Data
Premium
Company Announcements
Moleculin Biotech Reports Promising Annamycin AML Trial Data
3M ago
8K
MBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >